Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study
Titel:
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study
Auteur:
Wainberg, Zev A Enzinger, Peter C Kang, Yoon-Koo Qin, Shukui Yamaguchi, Kensei Kim, In-Ho Saeed, Anwaar Oh, Sang Cheul Li, Jin Turk, Haci Mehmet Teixeira, Alexandra Borg, Christophe Hitre, Erika Udrea, Adrian A Cardellino, Giovanni Gerardo Sanchez, Raquel GuardeƱo Collins, Helen Mitra, Siddhartha Yang, Yingsi Catenacci, Daniel V T Lee, Keun-Wook